Comparison of the efficacy and tolerability of telmisartan 40 mg vs. enalapril 10 mg in the treatment of mild-to-moderate hypertension: A multicentre, double-blind study in Taiwanese patients

International Journal of Clinical Practice, Supplement

Volumn , Issue 145, 2004, Pages 29-34

  Chen, Jyh Hong ^a   Cheng, J J ^b   Chen, C Y ^c   Chiou, H C ^d   Huang, T Y ^e   Tsai, C D ^f   Fu, M M Y ^g   Cherng, W J ^g  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Antihypertensives; Enalapril; Hypertension; Telmisartan

Indexed keywords

ENALAPRIL; PLACEBO; TELMISARTAN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TAIWAN;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 10344262553     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. de Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
2. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.
3. Heel RC, Brogden RN, Speight TM, et al. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 20: 409-52.
4. Romankiewicz JA, Brogden RN, Heel RC, et al. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs 1983; 25: 6-40.
5. Brogden RN, Todd PA, Sorkin EM. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 36: 540-600.
6. Todd PA, Heel RC. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198-248.
7. Todd PA, Goa KL. Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure. Drugs 1989; 37: 141-61.
8. Todd PA, Goa KL. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992; 43: 346-81.
9. Rault R. Intolerance to ACE-inhibitor drugs. Nephron 2001; 87: 198.
10. Smith DH. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther 2002; 24: 1484-501.
11. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000; 35 (Suppl. 3): S23-S26.
12. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141-4.
13. Gao M, Ikeda K, Hattori H, et al. Cardiovascular risk factors emerging in Chinese populations undergoing urbanization. Hypertens Res 1999; 22: 209-15.
14. Pan WH, Chang HY, Yeh WT, et al. Prevalence, awareness and control of hypertension in Taiwan: results of Nutrition and Health Survey In Taiwan (NAHSIT) 1993-96. J Hum Hypertens 2001; 15: 793-8.
15. Chan JC, Critchley JA, Tomlinson B, et al. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80.
16. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001: 10 (Suppl. 1): 6-11.
17. Sharpe M, Jarvis B, Goa KL. Telmisartan. A review of its use in hypertension. Drugs 2001; 61: 1501-29.
18. Just PM. The positive association of cough with angiotensin-converting enzyme inhibitors. Pharmacotherapy 1989; 9: 82-7.
19. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000; 40: 1380-90.
20. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229-40.
21. Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999; 53: 175-8.
22. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999; 17: 293-302.
23. Hannedouche T, Chanard J, Baumelou B, et al. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001; 2: 246-54.
24. Amerena J, Pappas S, Ouellet JP, et al. ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res 2002; 30: 543-52.